<DOC>
	<DOCNO>NCT00282399</DOCNO>
	<brief_summary>The purpose study determine dose decitabine maximizes genomic demethylation patient Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>A Clinical Trial Decitabine Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>Phase I : The purpose study determine subcutaneous dos decitabine administer twice daily 5 day maximizes genomic demethylation patient MDS Phase II : To evaluate hematological response dose select Phase I portion study . Note : This study plan Phase 1/2 study Phase 1 part conduct due change product development strategy</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 . 2 . Confirmed diagnosis MDS nonproliferative chronic myelomonocytic leukemia ( CMML ) . 1 . Prior therapy decitabine azacytidine ( Vidaza ) . 2 . Experimental standard drug treatment MDS within 28 day first day study drug treatment . 3 . Clinically significant anemia . 4 . Prior history malignancy MDS . 5 . Any active infection . 6 . Radiotherapy within 14 day prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MGI Pharma</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>